How India Exports Ifosfamide to the World

Ifosfamide was first approved by the FDA on December 30, 1988, under the brand name Ifex, manufactured by Baxter Healthcare. The FDA has since approved generic versions, with Fresenius Kabi USA receiving approval on May 28, 2002, for 1g and 3g vials. As of February 12, 2026, these generics are available in the market.

The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for ifosfamide, indicating a competitive generic market. Given that 152 Indian exporters are actively involved in the ifosfamide trade, compliance with FDA regulations, including Good Manufacturing Practices (GMP) and proper labeling, is crucial to maintain market access.

In the European Union, ifosfamide-containing medicines, such as Holoxan, are subject to EMA regulations. A manufacturing issue identified during a regulatory inspection in September 2025 led to a temporary halt in production, resulting in a shortage expected to last until Q1 2027. This shortage affects all EU/EEA Member States. (ema.europa.eu)

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring marketing authorization holders to adhere to EU GMP guidelines. Indian exporters must ensure compliance with these standards to maintain access to the UK market.

Ifosfamide is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in treating various cancers. The 10th List (2025) specifies its use for conditions such as anaplastic large cell lymphoma, Burkitt lymphoma, Ewing sarcoma, nephroblastoma, osteosarcoma, ovarian germ cell tumors, rhabdomyosarcoma, and testicular germ cell tumors. (iris.who.int)

Compliance with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for Indian exporters to meet global quality requirements.

In India, ifosfamide is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing under the Drug Price Control Order (DPCO). Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for exporting ifosfamide, ensuring compliance with national regulations.

The original patents for ifosfamide have expired, leading to a competitive generic market. As of February 4, 2026, there are no active U.S. patents for ifosfamide, allowing multiple manufacturers to produce and market generic versions.

In September 2025, a regulatory inspection at a European manufacturing site led to a temporary halt in ifosfamide production, causing a shortage expected to last until Q1 2027. (ema.europa.eu)

In February 2026, the FDA updated its records to confirm the availability of generic ifosfamide versions, reflecting a stable supply in the U.S. market.

These developments highlight the dynamic nature of the ifosfamide market, emphasizing the need for Indian exporters to stay informed about regulatory changes and market conditions to maintain and expand their global presence.

Ifosfamide, an alkylating agent used in chemotherapy, relies on Active Pharmaceutical Ingredients (APIs) that are predominantly manufactured in India. However, the production of these APIs is heavily dependent on Key Starting Materials (KSMs) and intermediates, many of which are imported from China. This dependency poses a significant risk, as any disruption in the supply of these materials can halt API production. For instance, in July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing a ripple effect that impacted global pharmaceutical supply chains, including those in India.

The concentration of KSM production in China is notable, with the country controlling approximately 70–80% of the global KSM supply. This monopolization means that any geopolitical tensions, trade restrictions, or internal policy changes within China can have immediate and profound effects on the availability and cost of essential raw materials for Ifosfamide production in India.

The export market for Ifosfamide from India is notably concentrated among a few key players. The top five exporters—VIVALIA REMEDIES PRIVATE LIMITED, UNITED BIOTECH PRIVATE LIMITED, GETWELL PHARMACEUTICALS, KWALITY PHARMACEUTICALS LIMITED, and DAB PHARMA—collectively account for 62.3% of the total export value, with VIVALIA REMEDIES alone contributing 24.9%. This high level of supplier concentration increases the risk of supply chain disruptions, as issues affecting any of these major exporters could significantly impact the overall availability of Ifosfamide in international markets.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing of critical APIs and reducing reliance on imports. As of March 2025, the PLI scheme for bulk drugs has led to import savings of ₹1,362 crore and has spurred investments exceeding initial commitments, indicating a positive trend towards self-sufficiency. However, the effectiveness of this scheme in diversifying the supplier base for Ifosfamide remains to be fully realized.

Global shipping routes, such as the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Any geopolitical tensions or conflicts in these regions can lead to delays and increased shipping costs, affecting the timely delivery of Ifosfamide exports. Additionally, ongoing trade tensions between major economies, such as the United States and China, can result in tariffs and trade barriers that indirectly impact the pharmaceutical supply chain by affecting the cost and availability of raw materials.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have occasionally issued shortage alerts for chemotherapy drugs, including Ifosfamide, highlighting the vulnerability of the supply chain. These shortages can stem from manufacturing issues, quality control problems, or supply chain disruptions, underscoring the need for robust risk management strategies.

• Diversify Raw Material Sources: Encourage the development of alternative suppliers for KSMs and intermediates to reduce dependency on a single country, thereby enhancing supply chain resilience.

• Strengthen Domestic Manufacturing: Leverage the PLI scheme to further incentivize the production of critical APIs and KSMs within India, aiming for self-sufficiency and reduced import reliance.

• Expand Supplier Base: Promote the growth of small and medium-sized pharmaceutical enterprises to decrease market concentration and mitigate risks associated with reliance on a few large exporters.

• Enhance Supply Chain Transparency: Implement advanced tracking and monitoring systems to identify potential disruptions early and develop contingency plans accordingly.

• Develop Strategic Reserves: Establish stockpiles of essential raw materials and finished products to buffer against short-term supply chain disruptions.

RISK_LEVEL: MEDIUM